Pfizer clinical trials belgium

Search for terms. Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. Last Update Posted : September 29, Study Description. The purpose of this study was to give access to postmenopausal women with estrogen sensitive primary breast cancer to exemestane for the adjuvant treatment of breast cancer after the use of tamoxifen and to collect all serious adverse events.

MedlinePlus related topics: Breast Cancer. Drug Information available for: Exemestane. Centers for Disease Control and Prevention CDC approved the boosters last week for three categories of Americans: those 65 or older; front-line workers such as teachers, health care workers and others whose jobs place them at risk of contracting COVID; and those ages 50 to 64 with underlying conditions.

Health care staff at other facilities, including home care and hospice facilities, are required to be inoculated by October 7. New York Governor Kathy Hochul has said she will call up medically trained National Guard members to deal with any staffing shortages that may arise if health care workers refuse to adhere to the mandatory vaccination deadlines. Workers who refuse vaccination without a valid doctor-approved request for a medical exemption, the governor's office said, will be terminated and not be eligible to receive unemployment benefits.

Elsewhere, South Korea announced Monday that in October, it will begin vaccinating youngsters ages 12 to 17 and give boosters to people ages 75 and older, according to the Reuters news agency. The booster program is prompted by a jump in COVID cases following the recent Korean holiday, Chuseok, a three-day fall harvest festival. The group said family members would tell their stories to the prime minister of how their loved ones caught the virus. A fourth member of the Brazilian delegation to the U.

National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Diagnostic Test: immunogenicity after first and second dose. Phase 4. Study Type :. Interventional Clinical Trial. Estimated Enrollment :. The research nurse administrating the vaccine is the only one who is not blinded.

Actual Study Start Date :. It is a randomized, double-blind, placebo-controlled study with two thirds of participants assigned to gene therapy. The one third of participants who are randomized to the placebo arm will have an opportunity for treatment with gene therapy at the beginning of the second year.

Detailed Description:. MedlinePlus related topics: Muscular Dystrophy. FDA Resources. Arms and Interventions. Placebo will be administered as a single IV infusion at Year 2 for Cohort 1. Approximately one third of participants will be randomized to Cohort 2. Placebo will be administered as a single IV infusion at Year 1 for Cohort 2. Outcome Measures. Mini-dystrophin distribution from a muscle biopsy will be assessed by immunofluorescence.

To count the skills that each child gained, based on the individual items of the NSAA. To count the skills that each child improved or maintained, based on the individual items of the NSAA.

Velocity is calculated based on the time that it takes to the rise from floor. Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Key inclusion criteria: Confirmed diagnosis of Duchenne muscular dystrophy by prior genetic testing Receiving a stable daily dose at least 0.

Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.